BioSpace News Archive

BioCapital

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VCA-894A for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within IGHMBP2.

June 1, 2023
·
5 min read
BioCapital

Vanda Pharmaceuticals Announces Presentations at SLEEP 2023

Vanda Pharmaceuticals Inc. announced participation at SLEEP 2023, to be held in Indianapolis, IN from June 3 – 7, 2023.

June 1, 2023
·
1 min read
AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera

With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell’Ospedale di Bergamo under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b in polycythaemia vera, a rare blood cancer.

June 1, 2023
·
4 min read
Policy

NMPA accepted Akeso’s ebronucimab (PCSK9) marketing application in two cardiovascular indications

Akeso Inc. announced that China’s National Medical Products Administration has accepted its New Drug Application for its fully human anti-PCSK9 monoclonal antibody ebronucimab for 2 indications 1) primary hypercholesterolemia and mixed hyperlipidemia, and 2) heterozygous familial hypercholesterolemia.

June 1, 2023
·
2 min read